In the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), lower rates of myocardial infarction, stroke and death were found following Rosuvastatin regimens in otherwise healthy adults with baseline CRP level ≥ 2mg/L and no hyperlipidemia (54). This evidence concerns the gene CRP and myocardial infarction.